Advertisement

Biologics – An Overview

  • Ian C. Scott
  • James B. Galloway
  • David L. Scott
Chapter

Abstract

The biologics used in inflammatory arthritis are genetically engineered proteins derived from human genes. They inhibit specific components of the immune system, which play pivotal roles in driving or inhibiting inflammation in arthritis. Unlike conventional drugs that modify the immune system as a whole, biologics affect specific components of the immune system. Theoretically this targeted approach is both more specific in its effects and causes fewer adverse events. However, in reality the complex interactions of cytokines and the multiplicity of cytokine targets means it is difficult to predict the effectiveness and toxicity of cytokine-based interventions such as biologics. There are currently six different classes of biologics available for the treatment of inflammatory arthritis patients. Each inhibits a different aspect of the immune driven inflammatory pathway. This chapter will provide a broad overview of the available biologics, the current treatment pathways dictating their prescribing in the UK and the health economics issues surrounding their use.

Keywords

Biologics Anti-TNF Rituximab Tocilizumab Abatacept Side-Effects 

References

  1. 1.
    Scott DL, Symmons DP, Coulton BL, Popert AJ. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet. 1987;1:1108–11.PubMedCrossRefGoogle Scholar
  2. 2.
    Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344:1105–10.PubMedCrossRefGoogle Scholar
  3. 3.
    Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594–602.PubMedCrossRefGoogle Scholar
  4. 4.
    National Institute for Health and Care Excellence. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. NICE Website. 2007. http://www.nice.org.uk/TA130. Accessed 20 Apr 2014.
  5. 5.
    Scott IC. Risk prediction in rheumatoid arthritis. Unpublished thesis, King’s College London; 2014.Google Scholar
  6. 6.
    Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26–37.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2015

Authors and Affiliations

  • Ian C. Scott
    • 1
  • James B. Galloway
    • 2
  • David L. Scott
    • 2
  1. 1.Molecular and Cellular Biology of InflammationKing’s College LondonLondonUK
  2. 2.RheumatologyKing’s College HospitalLondonUK

Personalised recommendations